Esperion Therapeutics, Inc. (ESPR) Stock
Esperion Therapeutics, Inc.
Company profile
Esperion Therapeutics reported revenue of $403.14 million for fiscal year 2025, up 21.3% from fiscal year 2024. Our analysis of its filings shows revenue growing from $116.33 million in fiscal year 2023 to $403.14 million in fiscal year 2025, 86.2% a year on average.
What stands out
- It reported a net loss in each of its last 5 fiscal years; the loss narrowed from $51.75 million in fiscal year 2024 to $22.68 million in fiscal year 2025.
- Its average diluted share count rose 11.0% in fiscal year 2025, from 187.2 million to 207.9 million shares.
- Revenue in fiscal year 2025 was the highest of the last 5 fiscal years.
Figures from company filings; latest fiscal year ended December 31, 2025.
Largest shareholders
- BlackRock Advisors LLC6.57%
- Wasatch Advisors LP6.13%
- Wasatch Advisors LP6.13%
- Two Seas Capital LP4.43%
- OrbiMed Advisors Private Equity4.11%
Share of the company, as of May 18, 2026
In the news
- Esperion Reaches Settlement Agreement with Seventh ANDA Filer Not to Market Generic Version of NEXLETOL® (bempedoic acid) & NEXLIZET® (bempedoic acid & ezetimibe) Prior to April 19, 2040GlobeNewsWire ·
- Esperion Reaches Settlement Agreement with Sixth ANDA Filer Not to Market Generic Version of NEXLETOL® (bempedoic acid) & NEXLIZET® (bempedoic acid & ezetimibe) Prior to April 19, 2040GlobeNewsWire ·
- Esperion Therapeutics Clears Key Hurdle as Stockholders Approve Essence MergerMarketBeat ·
- Esperion to Participate in Upcoming 44th Annual J.P. Morgan Healthcare Conference
How much revenue does Esperion Therapeutics make?
Esperion Therapeutics reported $403.14 million in revenue for fiscal year 2025, up 21.3% from $332.31 million in fiscal year 2024.
What companies are similar to Esperion Therapeutics?
Listed companies of a similar size in the same industry (metabolic process treatment drugs) include BioMarin Pharmaceutical Inc. (BMRN), Disc Medicine, Inc. (IRON), NewAmsterdam Pharma Company N.v. (NAMS), Maze Therapeutics, Inc. (MAZE).
Has Esperion Therapeutics made a profit in recent years?
Net income by fiscal year: FY2021, a loss of $269.11 million; FY2022, a loss of $233.66 million; FY2023, a loss of $209.25 million; FY2024, a loss of $51.75 million; FY2025, a loss of $22.68 million. It reported a net loss in each of these 5 years.
How has Esperion Therapeutics' revenue changed over the last 5 fiscal years?
Revenue by fiscal year: FY2021, $78.45 million; FY2022, $75.48 million; FY2023, $116.33 million; FY2024, $332.31 million; FY2025, $403.14 million.
Data as of .
How to cite: DataPorium, “Esperion Therapeutics, Inc. (ESPR)”, data as of May 18, 2026, https://dataporium.tech/stocks/ESPR